WOA Advances Lupin Production with Proeon Framework Agreement

• Non-binding framework agreement with Proeon Foods signed
• Strong intellectual property protections secured
• Proeon granted exclusive Indian distribution rights conditional on commercial production
• Agreement supports WOA’s shift to lower-cost, capital-light manufacturing
• WOA continues talks with other prospective manufacturing partners

WOA Moves Closer to Capital-Light Lupin Production

Wide Open Agriculture Ltd (ASX:WOA) has formalised a non-binding framework agreement with Dutch-Indian plant protein manufacturer Proeon Foods B.V., marking a key milestone in its strategic pivot away from capital-intensive production. The deal sets the stage for contract manufacturing of WOA’s proprietary lupin-based ingredients, a move designed to improve production economics and reduce costs.

Proeon, with manufacturing operations in the Netherlands and Pune, India, was chosen for its established footprint and expertise in plant protein ingredients from mung bean and peanut. The framework agreement includes binding intellectual property protections, allowing both companies to share technical information and collaborate on trial production without risking WOA’s proprietary technology.

Exclusive Distribution Rights and Joint Venture Prospects

Under the agreement, Proeon gains exclusive rights to distribute WOA’s lupin products in India, contingent on WOA’s approval of commercial production. This exclusivity applies for a minimum two-year period, reflecting India’s strategic importance as a manufacturing and marketing hub for WOA’s lupin platform.

Both parties also intend to explore a large-scale manufacturing joint venture in India, aiming to scale production and co-product capabilities. This aligns with WOA’s broader goal of replacing its former German facility’s negative margins and limited co-product output with a more capital-efficient model.

Ongoing Partner Search Amid Strategic Shift

While the Proeon agreement is a significant step forward, it remains non-binding except for IP and exclusivity provisions. WOA continues to engage with other potential contract manufacturing partners, ensuring similar IP protections before advancing technical discussions. The company is focused on securing a long-term partner best suited to its lupin protein platform, with no minimum order or exclusivity commitments binding WOA at this stage.

WOA’s CEO Craig Swan highlighted the collaboration’s potential, noting that Proeon’s capabilities could be pivotal in determining the preferred manufacturing partner. This framework follows a series of strategic moves by WOA, including the wind-down of its German production facility and a shift toward contract manufacturing in Asia to boost scale and cost efficiency.

Proeon’s founder Kevin Parekh expressed enthusiasm about working with WOA, praising the lupin protein technology as an underutilised but promising ingredient in the plant protein space.

Next Steps Toward Commercialisation

With IP protections now secured, WOA and Proeon will share detailed technical data and begin trial production phases. Commercial terms such as pricing, delivery, and invoicing remain to be negotiated, with no fixed timetable set for a definitive agreement.

WOA’s ongoing discussions with other manufacturers may lead to additional framework agreements, reflecting a cautious yet proactive approach to finalising its contract manufacturing strategy.

Bottom Line?

WOA’s partnership framework with Proeon signals a crucial advance in its quest for a scalable, cost-effective lupin production model, but the transition hinges on successful trials and final commercial terms.

Questions in the middle?

• Will Proeon’s manufacturing capabilities meet WOA’s scale and quality requirements during trial phases?
• How quickly can WOA and Proeon negotiate and execute a binding contract following technical evaluations?
• Could WOA’s engagement with multiple manufacturers lead to a competitive bidding dynamic or delay final partner selection?